Monte Rosa Therapeutics
GLUE
About: Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.
Employees: 142
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
1,510% more call options, than puts
Call options by funds: $483K | Put options by funds: $30K
194% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 17
59% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 17
10% more funds holding
Funds holding: 105 [Q1] → 115 (+10) [Q2]
4.35% more ownership
Funds ownership: 96.77% [Q1] → 101.12% (+4.35%) [Q2]
2% more capital invested
Capital invested by funds: $276M [Q1] → $281M (+$4.32M) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 3 [Q1] → 3 (+0) [Q2]
Financial journalist opinion
Based on 5 articles about GLUE published over the past 30 days
